A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

Bettina Proneth, Federico P. Portillo, Carrie Haskell-Luevano

Research output: Contribution to journalArticle

Cite this